Drug Search Results

Opicinumab

Alternative Names: opicinumab, biib033, biib-113, biib113, biib 113
Latest Update: 2024-03-04
Latest Update Note: News Article

Product Description

Biogen is developing Opicinumab as a treatment for Multiple Sclerosis. (Sourced from: https://investors.biogen.com/news-releases/news-release-details/biogen-announces-affinity-phase-2-trial-initiation-opicinumab)

Mechanisms of Action: OGA Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Opicinumab

Countries in Clinic: Sweden, United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Alzheimer Disease

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
276HV101	P1	Completed	Alzheimer Disease	2023-07-10	43%

Recent News Events

Date	Type	Title
06/10/2022	PubMed	Novel Drugs in a Pipeline for Progressive Multiple Sclerosis.
03/04/2024	News Article	Biogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) 2024 Annual Meeting
01/31/2024	News Article	Biogen to Realign Resources for Alzheimer's Disease Franchise
05/01/2023	PubMed	Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
02/01/2022	PubMed	[Optic neuritis: aetiopathogenesis, diagnosis, prognosis and management].
10/13/2021	News Article	New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions